Edition:
United Kingdom

Corvus Pharmaceuticals Inc (CRVS.OQ)

CRVS.OQ on NASDAQ Stock Exchange Global Market

10.29USD
17 Jul 2018
Change (% chg)

$0.04 (+0.39%)
Prev Close
$10.25
Open
$10.24
Day's High
$10.57
Day's Low
$10.24
Volume
15,980
Avg. Vol
42,403
52-wk High
$17.54
52-wk Low
$7.45

Chart for

About

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-onc... (more)

Overall

Beta: --
Market Cap(Mil.): $322.59
Shares Outstanding(Mil.): 29.19
Dividend: --
Yield (%): --

Financials

  CRVS.OQ Industry Sector
P/E (TTM): -- 214.90 33.15
EPS (TTM): -2.56 -- --
ROI: -41.87 -3.85 13.23
ROE: -42.22 -5.38 15.27

BRIEF-Corvus Pharmaceuticals Q1 Loss Per Share $0.63

* CORVUS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

03 May 2018

BRIEF-Adams Street Partners Reports 15.5 Pct Stake In Corvus Pharma

* ADAMS STREET PARTNERS, LLC REPORTS 15.5 PERCENT STAKE IN CORVUS PHARMACEUTICALS INC AS OF MARCH 12, 2018 - SEC FILING‍​

21 Mar 2018

BRIEF-BVF Partners Reports 6.7 Pct Passive Stake In Corvus Pharmaceuticals

* BVF PARTNERS L.P. REPORTS 6.7 PERCENT PASSIVE STAKE IN CORVUS PHARMACEUTICALS INC AS OF MARCH 8, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2G67UVx) Further company coverage:

19 Mar 2018

BRIEF-Corvus Pharma Announces Pricing Of Public Offering Of Common Stock

* CORVUS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

08 Mar 2018

BRIEF-Corvus Pharma Announces Proposed Public Offering Of Common Stock

* CORVUS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

07 Mar 2018

BRIEF-Corvus Pharmaceuticals Qtrly Net Loss Per Share $0.58

* CORVUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

01 Mar 2018

Earnings vs. Estimates